LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Files An 8-K Other EventsItem 8.01 Other Events.
LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Files An 8-K Other Events
On March 1, 2017, we entered into a worldwide platform license agreement with bluebird bio, Inc. (NASDAQ: BLUE). Under the license, bluebird will be able to use the OmniRat®, OmniMouse® and OmniFlic® platforms to discover fully human mono- and bispecific antibodies and antibody fragments. We are eligible to receive annual platform access payments, development milestone payments and royalties for each product incorporating an OmniAb antibody. Bluebird will be responsible for all costs related to the programs. We previously disclosed rights to a single-antibody partnership had been licensed to bluebird but this agreement gives bluebird full access to the OmniAb platform.
About LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND)
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus. LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Recent Trading Information
LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) closed its last trading session 00.00 at 103.65 with 501,628 shares trading hands.
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus. LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Recent Trading Information
LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) closed its last trading session 00.00 at 103.65 with 501,628 shares trading hands.